Publication Topic

Davison NJ, Guthrie NL, Medland S, Lupinacci P, Nordyke RJ, Berman MA. 2024. Cost-effectiveness analysis of a prescription digital therapeutic in Type 2 diabetes. Adv Ther 41(2):806-825; doi: 10.1007/s12325-023-02752-2. PMID: 38170435.

Klosterbuer A, Cekola P, Neutel JM, Jiang X, Cohen SS, Torres KA. Diabetes specific ONS led to a blunted postprandial glucose response and a 26% reduction in peak blood glucose levels compared to a standard ONS. Presented at FNCE 2022 Food & Nutrition Conference & Expo, Orlando, FL, October 2022.

Nordyke RJ, Appelbaum K, Berman MA.  2019. Estimating the impact of novel digital therapeutics in Type 2 diabetes and hypertension: Health economic analysis. J Med Internet Res 21(10):e15814; doi: 10.2196/15814. PMID: 31937249.

Brixner D, Ermakova A, Xiong Y, Sieradzan R, Sacks NC, Cyr PL, Taylor S. 2019. Clinical and economic outcomes of patients with type 2 diabetes on multiple daily injections of basal-bolus insulin (MDI) therapy: A retrospective cohort study. Clin Therapeut 41(2):303–313; doi: 10.1016/j.clinthera.2018.12.014.

Ludden T, Ermakova A, Xiong Y, Cyr PL, Sieradzan R, Sacks NC, Taylor SD. Comparison of healthcare resource utilization for multiple-daily injections (MDI) with basal and bolus insulin therapy versus non-MDI therapy in patients with Type 2 diabetes. Poster presentation at Academy of Managed Care Pharmacy Annual Research Meetings, Boston, MA, 2018.

Ludden T, Ermakova A, Xiong Y, Cyr PL, Sieradzan R, Sacks NC, Taylor SD. Comparison of healthcare resource utilization and clinical status among Type 2 diabetes patients using multiple-daily injection (MDI) insulin therapy vs. non-MDI therapy. ISPOR 23^rd Annual Conference, Baltimore MD, 2018.

Sacks NC, Liu Y, Sanyal A, DeFronzo R, Bhatt DL, Caplan, J… Cyr PL, et al. The economic burden of insulin resistance, obesity, and cardiovascular disease in Medicare beneficiaries 65 years of age and older. American Heart Association Scientific Sessions, Anaheim CA, 2017.